{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:17:32Z","timestamp":1791955052213,"version":"4.3.4"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/tp.0000000000001633","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T05:57:52Z","timestamp":1483682272000},"page":"916-923","source":"Crossref","is-referenced-by-count":20,"title":["Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis"],"prefix":"10.1097","volume":"101","author":[{"given":"Carmen","family":"Vinaixa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone I.","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210211","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Annals of internal medicine review eradication of hepatitis C virus infection and the development of hepatocellular carcinoma","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"R2-10-20210211","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R3-10-20210211","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"R4-10-20210211","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","author":"Poynard","year":"2013","journal-title":"J Hepatol"},{"key":"R5-10-20210211","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","article-title":"Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy","volume":"132","author":"Shiratori","year":"2000","journal-title":"Ann Intern Med"},{"key":"R6-10-20210211","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jvh.12534","article-title":"Treat chronic hepatitis C virus infection in decompensated cirrhosis\u2014pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy","volume":"23","author":"Bunchorntavakul","year":"2016","journal-title":"J Viral Hepat"},{"key":"R7-10-20210211","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"R8-10-20210211","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2036.2008.03620.x","article-title":"Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis","volume":"27","author":"Everson","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-10-20210211","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis c","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"R10-10-20210211","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"R11-10-20210211","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"R12-10-20210211","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1111\/j.1572-0241.2006.00743.x","article-title":"Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis","volume":"101","author":"Rincon","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R13-10-20210211","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cgh.2007.02.022","article-title":"Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis","volume":"5","author":"Roberts","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R14-10-20210211","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.cgh.2011.05.028","article-title":"Effects of a sustained virologic response on outcomes of patients with chronic hepatitis","volume":"9","author":"Ng","year":"2011","journal-title":"C. Clin Gastroenterol Hepatol"},{"key":"R15-10-20210211","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","article-title":"Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"R16-10-20210211","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP1807","article-title":"The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon\/ribavirin therapy","volume":"16","author":"D\u2019Ambrosio","year":"2011","journal-title":"Antivir Ther"},{"key":"R17-10-20210211","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating hepatitis C Virus infection in patients with cirrhosis differ with stage of portal hypertension","volume":"151","author":"Di Marco","year":"2016","journal-title":"Gastroenterology"},{"key":"R18-10-20210211","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"R19-10-20210211","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","article-title":"Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"135","author":"Maylin","year":"2008","journal-title":"Gastroenterology"},{"key":"R20-10-20210211","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/jvh.12578","article-title":"Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy","volume":"23","author":"Knop","year":"2016","journal-title":"J Viral Hepat"},{"key":"R21-10-20210211","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","article-title":"The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response","volume":"59","author":"D\u2019Ambrosio","year":"2013","journal-title":"J Hepatol"},{"key":"R22-10-20210211","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.510280333","article-title":"Predictors of patient and graft survival following liver transplantation for hepatitis C","volume":"28","author":"Charlton","year":"1998","journal-title":"Hepatology"},{"key":"R23-10-20210211","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199603283341302","article-title":"Long-term outcome of hepatitis C infection after liver transplantation","volume":"334","author":"Gane","year":"1996","journal-title":"N Engl J Med"},{"key":"R24-10-20210211","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"R25-10-20210211","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"key":"R26-10-20210211","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/gut.52.2.283","article-title":"Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence","volume":"52","author":"Bizollon","year":"2003","journal-title":"Gut"},{"key":"R27-10-20210211","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carri\u00f3n","year":"2007","journal-title":"Gastroenterology"},{"key":"R28-10-20210211","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/liv.13193","article-title":"Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis","volume":"37","author":"Martini","year":"2017","journal-title":"Liver Int"},{"key":"R29-10-20210211","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cgh.2010.10.036","article-title":"Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis","volume":"9","author":"Iacobellis","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R30-10-20210211","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R31-10-20210211","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R32-10-20210211","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"R33-10-20210211","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"R34-10-20210211","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"R35-10-20210211","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"R36-10-20210211","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S0168-8278(16)00195-1","article-title":"HCV eradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment; final results of the study of sofosbuvir plus ribavirin in patients with cirrhosis and portal hypertension","volume":"64","author":"Afdhal","year":"2016","journal-title":"J Hepatol"},{"key":"R37-10-20210211","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/gast.2002.35352","article-title":"Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy","volume":"123","author":"Fontana","year":"2002","journal-title":"Gastroenterology"},{"key":"R38-10-20210211","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7326\/0003-4819-150-3-200902030-00004","article-title":"Immediate listing for liver transplantation versus standard care for Child-Pugh stage b alcoholic cirrhosis: a randomized trial","volume":"150","author":"Vanlemmens","year":"2009","journal-title":"Ann Intern Med"},{"key":"R39-10-20210211","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"R40-10-20210211","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"R41-10-20210211","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"R42-10-20210211","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts.","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"R43-10-20210211","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1053\/jhep.2000.17924","article-title":"Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation","volume":"32","author":"Berenguer","year":"2000","journal-title":"Hepatology"},{"key":"R44-10-20210211","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1111\/ajt.12867","article-title":"Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index","volume":"14","author":"Biggins","year":"2014","journal-title":"Am J Transplant"},{"key":"R45-10-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-016-9707-8","article-title":"Abstracts of the 25th Annual Conference of APASL, February 20-24, 2016, Tokyo, Japan","volume":"10","author":"Gane","year":"2016","journal-title":"Hepatol Int"},{"key":"R46-10-20210211","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"},{"key":"R47-10-20210211","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/jlts.2003.50268","article-title":"Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C","volume":"9","author":"Wiesner","year":"2003","journal-title":"Liver Transpl"},{"key":"R48-10-20210211","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/lt.22175","article-title":"Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria","volume":"16","author":"Narang","year":"2010","journal-title":"Liver Transplant"},{"key":"R49-10-20210211","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.3748\/wjg.v22.i18.4547","article-title":"Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence","volume":"22","author":"Song","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R50-10-20210211","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/ajt.12209","article-title":"Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C","volume":"13","author":"Fontana","year":"2013","journal-title":"Am J Transplant"},{"key":"R51-10-20210211","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0034-1371084","article-title":"Case report of successful treatment of fibrosing cholestatic hepatitis c with sofosbuvir and ribavirin after liver transplantation","volume":"34","author":"Kim","year":"2014","journal-title":"Semin Liver Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000001633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:27:20Z","timestamp":1620977240000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201705000-00010"}},"subtitle":["Is the Point of No Return the Same Before and After Liver Transplantation? A Review"],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001633","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}